Updated
AgomAb TherapeuticsAGMB · Healthcare
$7.64+9.61%
Market cap$376M
IndustryBiotechnology
AgomAb Therapeutics (AGMB) Superinvestor holders
2 of the superinvestors we track hold AgomAb Therapeutics (AGMB) in their latest 13F filings, $21M in total.
Summary
The largest holder is Wilmot Harkey (Nantahala Capital Management), with $20M, 1.2% of the portfolio.
In their latest quarter: 2 added.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Wilmot Harkey Nantahala Capital Management |
Added | 1,568,188 | $20M | 1.2% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Added | 18,072 | $234,575 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 2 |
| Q1 2026 | 3 |
Questions about AgomAb Therapeutics
Which superinvestors own AgomAb Therapeutics?
2 of the superinvestors we track hold AgomAb Therapeutics (AGMB) in their latest 13F filings, $21M in total. Wilmot Harkey, Two Sigma.
Who is the largest superinvestor holder of AGMB?
The largest holder is Wilmot Harkey (Nantahala Capital Management), with $20M, 1.2% of the portfolio.
From AgomAb Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.